MYC and malignant colon neoplasm: Mammalian target of rapamycin (mTOR) contributes to colon cancer progression, and OSI-027, as an mTOR inhibitor, suppresses tumorigenesis in colon cancer via the c-Myc/FOXO3a/PUMA axis (Lou et al., 2022).